MedPath

A non-inferiority randomised clinical trial of the use of the smartphone-based health applications IBDsmart and IBDoc in the care of inflammatory bowel disease patients in New Zealand.

Not Applicable
Completed
Conditions
Inflammatory bowel disease
Inflammatory and Immune System - Other inflammatory or immune system disorders
Oral and Gastrointestinal - Inflammatory bowel disease
Registration Number
ACTRN12615000342516
Lead Sponsor
niversity of Otago
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
All
Target Recruitment
107
Inclusion Criteria

Confirmed UC or CD
At least 2 outpatient appointments in last 12 months.
<3 disease flares in last 12 months
Willing and able to provide written consent
18 years of age or over

18 years of age cutoff lowered to 16 on 15/1/16

Exclusion Criteria

Indeterminate colitis
Severe disease with close monitoring
Possible surgical intervention
Previous surgery
Pregnancy
Unwilling or unable to provide written consent

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Are IBDsmart/IBDoc acceptable to patients and doctors?<br>(composite)<br>Doctor completes usability questionnaire for doctors while patient completes usability questionnaire for patients.<br>Both the doctor and patient questionnaires are a mix of app specific questions about usability but also contain a validated questionnaire called the System Usability Scale (SUS) which produces a number between 0 and 100. SUS is standardized and therefore allows comparisons to be made between apps; it has an industry average of 68.[52 weeks post randomisation.];Are IBDsmart/IBDoc non-inferior to standard care delivered through outpatient clinic appointments only?<br>(Composite)<br>Inflammatory bowel disease questionnaire is the tool used to measure non-inferiority.[52 weeks post randomisation.]
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath